These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

584 related items for PubMed ID: 11754710

  • 1. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial.
    Geba GP, Weaver AL, Polis AB, Dixon ME, Schnitzer TJ, Vioxx, Acetaminophen, Celecoxib Trial (VACT) Group.
    JAMA; 2002 Jan 02; 287(1):64-71. PubMed ID: 11754710
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studies.
    Schnitzer TJ, Weaver AL, Polis AB, Petruschke RA, Geba GP, VACT-1 and VACT-2 (Protocols 106 and 150) Study Groups.
    J Rheumatol; 2005 Jun 02; 32(6):1093-105. PubMed ID: 15940774
    [Abstract] [Full Text] [Related]

  • 3. A comparison of rofecoxib versus celecoxib in treating pain after dental surgery: a single-center, randomized, double-blind, placebo- and active-comparator-controlled, parallel-group, single-dose study using the dental impaction pain model.
    Malmstrom K, Fricke JR, Kotey P, Kress B, Morrison B.
    Clin Ther; 2002 Oct 02; 24(10):1549-60. PubMed ID: 12462285
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo.
    Sheldon E, Beaulieu A, Paster Z, Dutta D, Yu S, Sloan VS.
    Clin Ther; 2005 Jan 02; 27(1):64-77. PubMed ID: 15763607
    [Abstract] [Full Text] [Related]

  • 5. Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial.
    Gibofsky A, Williams GW, McKenna F, Fort JG.
    Arthritis Rheum; 2003 Nov 02; 48(11):3102-11. PubMed ID: 14613272
    [Abstract] [Full Text] [Related]

  • 6. A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a Medicare Choice population.
    Becker RV, Burke TA, McCoy MA, Trotter JP.
    Clin Ther; 2003 Feb 02; 25(2):647-62. PubMed ID: 12749519
    [Abstract] [Full Text] [Related]

  • 7. A randomised, double-blind, clinical trial comparing the efficacy of nimesulide, celecoxib and rofecoxib in osteoarthritis of the knee.
    Bianchi M, Broggini M.
    Drugs; 2003 Feb 02; 63 Suppl 1():37-46. PubMed ID: 14506910
    [Abstract] [Full Text] [Related]

  • 8. Comparative evaluation of the effectiveness and tolerability of nimesulide versus rofecoxib taken once a day in the treatment of patients with knee osteoarthritis.
    Herrera JA, González M.
    Am J Ther; 2003 Feb 02; 10(6):468-72. PubMed ID: 14624289
    [Abstract] [Full Text] [Related]

  • 9. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib.
    Tannenbaum H, Berenbaum F, Reginster JY, Zacher J, Robinson J, Poor G, Bliddal H, Uebelhart D, Adami S, Navarro F, Lee A, Moore A, Gimona A.
    Ann Rheum Dis; 2004 Nov 02; 63(11):1419-26. PubMed ID: 15020310
    [Abstract] [Full Text] [Related]

  • 10. A 4-week randomized study of acetaminophen extended-release vs rofecoxib in knee osteoarthritis.
    Schnitzer TJ, Tesser JR, Cooper KM, Altman RD.
    Osteoarthritis Cartilage; 2009 Jan 02; 17(1):1-7. PubMed ID: 18640856
    [Abstract] [Full Text] [Related]

  • 11. Pain management in osteoarthritis: a focus on onset of efficacy--a comparison of rofecoxib, celecoxib, acetaminophen, and nabumetone across four clinical trials.
    Battisti WP, Katz NP, Weaver AL, Matsumoto AK, Kivitz AJ, Polis AB, Geba GP.
    J Pain; 2004 Nov 02; 5(9):511-20. PubMed ID: 15556830
    [Abstract] [Full Text] [Related]

  • 12. Comparison of the efficacy and tolerability of dexibuprofen and celecoxib in the treatment of osteoarthritis of the hip.
    Hawel R, Klein G, Singer F, Mayrhofer F, Kähler ST.
    Int J Clin Pharmacol Ther; 2003 Apr 02; 41(4):153-64. PubMed ID: 12708604
    [Abstract] [Full Text] [Related]

  • 13. Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group.
    Ehrich EW, Schnitzer TJ, McIlwain H, Levy R, Wolfe F, Weisman M, Zeng Q, Morrison B, Bolognese J, Seidenberg B, Gertz BJ.
    J Rheumatol; 1999 Nov 02; 26(11):2438-47. PubMed ID: 10555907
    [Abstract] [Full Text] [Related]

  • 14. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
    Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS.
    JAMA; 2000 Sep 13; 284(10):1247-55. PubMed ID: 10979111
    [Abstract] [Full Text] [Related]

  • 15. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group.
    Day R, Morrison B, Luza A, Castaneda O, Strusberg A, Nahir M, Helgetveit KB, Kress B, Daniels B, Bolognese J, Krupa D, Seidenberg B, Ehrich E.
    Arch Intern Med; 2000 Jun 26; 160(12):1781-7. PubMed ID: 10871971
    [Abstract] [Full Text] [Related]

  • 16. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
    Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer N, Kivitz A, van Ingen H, Brabant T, Fort JG, Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators.
    Arch Intern Med; 2005 Jan 24; 165(2):161-8. PubMed ID: 15668361
    [Abstract] [Full Text] [Related]

  • 17. The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care.
    Harley C, Wagner S.
    Clin Ther; 2003 Jan 24; 25(1):139-49. PubMed ID: 12637116
    [Abstract] [Full Text] [Related]

  • 18. Effects of perioperative administration of a selective cyclooxygenase 2 inhibitor on pain management and recovery of function after knee replacement: a randomized controlled trial.
    Buvanendran A, Kroin JS, Tuman KJ, Lubenow TR, Elmofty D, Moric M, Rosenberg AG.
    JAMA; 2003 Nov 12; 290(18):2411-8. PubMed ID: 14612477
    [Abstract] [Full Text] [Related]

  • 19. Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib and acetaminophen (paracetamol).
    Graham GG, Graham RI, Day RO.
    Curr Pharm Des; 2002 Nov 12; 8(12):1063-75. PubMed ID: 11945151
    [Abstract] [Full Text] [Related]

  • 20. The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence.
    Rahme E, Barkun AN, Toubouti Y, Bardou M.
    Gastroenterology; 2003 Aug 12; 125(2):404-12. PubMed ID: 12891542
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.